Share Prices & Company Research

Stockbroking

Verona Pharma

Current Price 43.50p Bid 35.00p Ask 45.00p Change 4.82%
Last Updated: 30/05/2020 10:36. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Verona Pharma is developing first in class drugs to treat respiratory disease such as COPD asthma and chronic severe cough

Financial Highlights Year Ended 31/12/2019

Revenue
£n/am
Operating Profit/Loss
£-41.08m
Dividend yield (%)
n/a
Total dividend for year
n/ap
Dividend cover
n/a
P/E Ratio
n/a

Key Personnel

Dr Sven Jan-Anders Karlsson
Chief Executive Officer
Mr Piers Morgan
Chief Financial Officer
Mr Ben Harber
Company Secretary
Mr David Ebsworth
Non-Executive Chairman
Dr Ken Cunningham
Non-Executive Director
Mr Anders Ullman
Non-Executive Director
Mr Andrew Sinclair
Non-Executive Director
Mr Mahendra Shah
Non-Executive Director
Mr Rishi Gupta
Non-Executive Director
Mr Vikas Sinha
Non-Executive Director

Stock Details

EPIC
VRP
ISIN
GB00BYW2KH80
Shares in Issue
106.48m
Market cap
£46.32m

Analyst Views (6)

Strong Buy
 
66.67%
Buy
 
0%
Hold
 
33.33%
Sell
 
0%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
43.50p
Bid Price
35.00p
Ask Price
45.00p
Volume
328,483
Change Today
2.00p
% Change Today
4.82%
Open
41.50p
Previous Close
43.50p
Intraday High
44.95p
Intraday Low
40.00p
52 Week High
75.00p
52 Week Low
31.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

News

Income Statement

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Continuing Operations
Revenue
n/a
n/a
Operating Profit/Loss
-41.08
-25.59
Net Interest
1.88
-1.46
Pre-Tax Profit
-39.21
-24.13
Profit After Tax from continuing operations
-31.94
-19.90
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
-31.94
-19.90
Attributable to:
Equity Holders of Parent Company
-31.94
-19.90
Minority Interests
n/a
n/a
Total Dividend Paid
n/ap
n/ap
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2019
31 Dec 2018
Basic
-30.30p
-18.90p
Diluted
-30.30p
-18.90p
Adjusted
-30.30p
-18.90p
Dividend per Share
n/ap
n/ap

Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
1.01
0.02
Intangible Assets
3.20
3.06
Investment Properties
n/a
n/a
Investments
n/a
n/a
Other Financial Assets
n/a
n/a
Other Non-Current Assets
n/a
n/a
Current Assets
Inventories
n/a
n/a
Trade & Other Receivables
10.17
6.96
Cash at Bank & In Hand
22.93
19.78
Current Asset Investments
7.82
44.92
Other Current Assets
n/a
n/a
Other Assets
n/a
n/a
Total Assets
45.13
74.75

Liabilities

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Current Liabilities
Borrowings
0.46
n/a
Other Current Liabilities
9.16
10.22
Total Current Liabilities
9.62
10.23
Non-Current Liabilities
Borrowings
0.49
n/a
Provisions
n/a
n/a
Other Non-Current Liabilities
1.16
1.10
Total Non-Current Liabilities
1.65
1.10
Other Liabilities
n/a
n/a
Total Liabilities
11.27
11.33

Net Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Net Assets
33.87
63.42

Capital & Reserves

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Share Capital
5.27
5.27
Share Premium Account
118.86
118.86
Other Reserves
10.36
7.92
Retained Earnings
-100.63
-68.63
Shareholders Funds
33.87
63.42
Minority Interests/Other Equity
n/a
n/a
Total Equity
33.87
63.42

Dividend History

Dividend Metrics

Year End Date
31 Dec 2019
31 Dec 2018
Dividend growth
n/a%
n/a%
Dividend yield
n/a%
n/a%
Dividend cover
n/a
n/a
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 22nd May 2020
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.